VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema.

about

VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema.

Item

http://www.wikidata.org/entity/Q47243737

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

VEGF-A gene polymorphisms and ...... s with diabetic macular edema.

@en

VEGF-A gene polymorphisms and ...... s with diabetic macular edema.

@nl

type

Item

label

VEGF-A gene polymorphisms and ...... s with diabetic macular edema.

@en

VEGF-A gene polymorphisms and ...... s with diabetic macular edema.

@nl

prefLabel

VEGF-A gene polymorphisms and ...... s with diabetic macular edema.

@en

VEGF-A gene polymorphisms and ...... s with diabetic macular edema.

@nl

P1476

VEGF-A gene polymorphisms and ...... ts with diabetic macular edema

@en

P2093

Fatih Özcura

http://www.w3.org/2001/XMLSchema#string

Haci Murat Sağdik

http://www.w3.org/2001/XMLSchema#string

Mehmet Tetikoğlu

http://www.w3.org/2001/XMLSchema#string

Serdar Aktas

http://www.w3.org/2001/XMLSchema#string

P2860

Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6

Vascular endothelial growth factor and diabetic macular edema.

Diabetic macular edema: pathogenesis and treatment.

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.

Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Long-term effects of ranibizumab on diabetic retinopathy severity and progression.

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

P2888

s10792-017-0738-5

P304

2381-2388

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10792-017-0738-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Zafer Yuksel

P577

2017-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29030794

http://www.w3.org/2001/XMLSchema#string